Who's running the show?
Ryan P. Hamer (BSc, MBA)
Ryan holds a Bachelor of Science from Swinburne University (Melbourne), a postgraduate degree in Management from Griffith University (Brisbane), and has undertaken specialist training in the U.S and the U.K. Ryan’s clinical and research interests focus on complex cortico-subcortical mapping for neuroplasticity in glioma patients, having previously introduced contemporary brain mapping techniques throughout Australia and Singapore. For Ryan, Neuroclast is a vehicle representative of his life's pursuit in applied clinical neuroscience, one that will foster a PhD and the sharing of knowledge and education in science, electrophysiology, and medical devices. Learn more about Neuroclast's research.
Ryan is a clinical neuroscientist, healthcare executive and medical device enthusiast based in Melbourne, Australia. Having been involved in clinical neurophysiology for over a decade, he has individually served as Clinical Director and Business Development Manager for two multinational clinical neuroscience and healthcare companies, and has been an invited speaker at medical conferences and meetings around Australia, Asia and South Africa. Ryan is also a Clinical Lecturer with the Faculty of Health and Medicine at the University of Sydney, and Unit Coordinator for intraoperative neurophysiology units as part of the Master of Medicine program. In addition to these roles, Ryan was also elected as President of the Intraoperative Neurophysiology Society of Asia-Pacific (INSA) for 2020-2021.
Hamer R. P. & Yeo T. T. (2022). Current status of neuromodulation-induced cortical prehabilitation and considerations for treatment pathways in lower-grade glioma surgery. Life, 12(4), 466:491.
Hamer R. P. et al. (2020). Optimizing the onco-functional balance in supratentorial brain tumour surgery: a single institution's initial experience in cortico-subcortical mapping and monitoring in Singapore. Journal of Clinical Neuroscience, 79, 224-230.
'Neurosurgeons aren't super-people'. Profile & interview with Prof Kate Drummond, Melbourne AUS.
'I'd like to be a rock-star'. Profile & interview with A/ Prof Jay Shills, Chicago US.
'This is not science fiction'. Profile & interview with Prof Hugues Duffau, Montpellier FR.
I’ve spent a considerable amount of my career observing neurosurgeons treat brain cancer patients. That’s why Neuroclast exists; to provide functional information to surgeons who help ensure that these patients maintain a good quality of life. At the moment we have a niche product portfolio and data infrastructure that will permit clinicians and hospitals to optimise patient outcomes and publish their own results with ease. Nexstim in particular represents a tremendous opportunity for me as a scientist, not only to introduce new neuro-imaging techniques in the ANZ region, but also to contribute to our over-arching pursuit to help preserve life with neuro-functional insight, and contribute to the new era of functional localisation of the brain.
icon·o·clast | ʌɪˈkɒnəklast
A person who challenges settled beliefs or institutions. If you describe someone as an iconoclast, you mean that they often question dogmatic beliefs and standards that are generally accepted by society, in order to benefit society.
neu·ro | nu̇r-ō
Of or relating to the human nervous system.
neu·ro·clast | nu̇r-ō-ˌklast
the pursuit of understanding, generated by a collective of persons who respectfully challenge settled beliefs, dogmas or institutions related to applied clinical neuroscience and applications of medical technology, and in collaboration with clinicians, to optimize clinical outcomes for patients.
What's in a name?
Why are we here?
Our goal is to facilitate access to technologies that might reduce the impact of debilitating neurologic injury. A lot of the time these technologies are related to mapping the human brain, though this also involves technology relating to virtual reality and electrophysiology.
First and foremost, we invest in our employees. We're committed to building an environment that fosters professional growth in order to meet the needs of clinicians and patients.
We invest in the technology of our business partners, and generate revenue for new business partners, to introduce various medical technologies to ANZ.
We will also distribute a portion of revenue towards novel research and development relating to neuroscience, neurosurgery and electrophysiology. This will also involve co-sponsorship of research funding with academic and medical institutions.
As a company, we are dedicated to finding ways to assist clinicians in their plight against brain cancer and neurodegenerative disease, and meaningfully contributing to clinical education and research. More often than not, this means partnering with world-class medical device companies around the world to introduce their technology in ANZ.
We look to employ people that are independently minded and lateral thinkers that are solutions-oriented. We are also hell-bent on the fostering and development of graduate professionals entering the healthcare and medtech industry.
We're also big on transparency. We're a small but growing business, and it's important we include our prospective customers with how we're distributing revenue from your interest in our products and services.
The company also expects to align with various charities and fundraising efforts for these charities to increase awareness of causes and centres related to neurodegenerative disease.